Explore
Search ClinicalTrials.gov
Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.
Results for “Novartis”
- A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.Active Not Recruiting
Sponsor: Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
United States, Argentina, Australia, Austria, Belgium +37 more
- Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia GravisActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Generalized Myasthenia Gravis
United States, France, Japan, United Kingdom
Sponsor: Novartis Pharmaceuticals
Immune Thrombocytopenia
United States
Sponsor: Novartis Pharmaceuticals
Hidradenitis Suppurativa
United States, Argentina, Australia, Canada
- Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host DiseaseActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Steroid-refractory Acute Graft Versus Host Disease
China
Sponsor: Novartis Pharmaceuticals
Schnitzler Syndrome
Japan
Sponsor: Novartis Pharmaceuticals
Cutaneous Lichen Planus
United States, Australia
- A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic ArthritisNot Yet Recruiting
Sponsor: Novartis Pharmaceuticals
Moderate to Severe Psoriatic Arthritis
Sponsor: Novartis Pharmaceuticals
Leukemia, Chronic Myeloid
Germany
- Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic SclerosisActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Scleroderma, Diffuse
United States, Argentina, Australia, Austria, Belgium +17 more
- Early Intensive Lipid-Lowering With Inclisiran for Plaque Stabilization in Acute Coronary SyndromeNot Yet Recruiting
Sponsor: Seoul National University Bundang Hospital
Acute Coronary Syndromes (ACS)
South Korea
- A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)Active Not Recruiting
Sponsor: Novartis Pharmaceuticals
Lupus Erythematosus, Systemic · Lupus Nephritis
United States, Argentina, Australia, Austria, Brazil +21 more
- Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPRecruiting
Sponsor: Novartis Pharmaceuticals
Chronic Myelogenous Leukemia · Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
United States, Australia, Brazil, Canada, China +8 more
- An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple SclerosisActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
Australia, France, Germany, Italy, Spain +1 more
Sponsor: Novartis Pharmaceuticals
Participants With Moderate and Severe Renal Impairment and Healthy Participants
Sponsor: Novartis Pharmaceuticals
Oligometastatic Prostate Cancer (OMPC)
United States, Argentina, Australia, Austria, Belgium +22 more
- A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab EmiratesNot Yet Recruiting
Sponsor: Novartis Pharmaceuticals
Hypertension
Sponsor: American Society of Clinical Oncology
Lymphoma, Non-Hodgkin · Multiple Myeloma · Advanced Solid Tumors
United States, Puerto Rico
- A Study of Clinical Practice and Real-world Care of Patients Treated With mTOR, PI3K, and MEK Inhibitors for Extracranial Vascular AnomaliesNot Yet Recruiting
Sponsor: Novartis Pharmaceuticals
Vascular Anomalies
Sponsor: Novartis Pharmaceuticals
Huntington Disease
United States, Argentina, Australia, Belgium, Bulgaria +17 more
- A Real-World Medical Chart Review of Spinal Muscular Atrophy Patients Treated With Onasemnogene Abeparvovec in Saudi ArabiaNot Yet Recruiting
Sponsor: Novartis Pharmaceuticals
Spinal Muscular Atrophy
- An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Active Not Recruiting
Sponsor: Novartis Pharmaceuticals
Metastatic Hormone-sensitive Prostate Cancer
United States, Australia, Brazil, Canada, China +10 more
- A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in SpainNot Yet Recruiting
Sponsor: Novartis Pharmaceuticals
Complement 3 Glomerulopathy
Sponsor: Duke University
Percutaneous Coronary Intervention · Peripheral Endovascular Intervention
United States
- A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
United States, Australia, Austria, Belgium, Bulgaria +24 more